NCT00051662View on ClinicalTrials.gov

Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis

PHASE1CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 29, 2004

Conditions

Psoriatic Arthritis

Interventions

DRUG

efalizumab

All Listed Sponsors

lead

XOMA (US) LLC

INDUSTRY

NCT00051662 - Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis | Biotech Hunter | Biotech Hunter